Pavel Bogomolov, MD, Ph.D (he/him/his)

Head of hepatology dept.
M.F. Vladimirsky Moscow Regional Research and Clinical Institute, Moscow, Russian Federation
Moscow, Moskva, Russia

Since 2004 head of hepatology dept. of Moscow regional researche-clinical institute n.a. Vlsdimirsky.
Author of the first publication about teratment patients with HDV-infection by bulevirtide (myrcludex B).

Disclosure(s): No financial relationships to disclose

Presentation(s):

• 83 - Predictors of Undetectable HDV RNA 48 weeks after completion of finite treatment with Bulevirtide and Pegylated-Interferon Alpha 2a

  Thursday, October 17, 2024
  10:45 AM – 11:00 AM US PT

• 521 - Efficacy and safety of buleviritide monotherapy for chronic hepatitis D in patients with and without cirrhosis: results from the week 144 interim analysis of a phase 3 randomized study

  Saturday, October 19, 2024
  12:20 PM – 12:25 PM US PT